Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Inclusion Criteria * Subject has provided informed consent prior to initiation of any study specific activities or procedures. * Male or female subjects age ≥ 18 years * First or second relapse of multiple myeloma by IMWG criteria (subjects refractory to the most recent line of therapy, excluding carfilzomib, are eligible) * Refractory to lenalidamide * Measurable disease with at least 1 of the following assessed within 28 days prior to enrollment: * IgG multiple myeloma: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL * IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL * urine M-protein ≥ 200 mg per 24 hours * in subjects without measurable serum or urine M-protein, serum-free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio * Must have at least a PR to at least 1 line of prior therapy * Prior therapy with proteasome inhibitors is allowed. Subjects receiving prior carfilzomib therapy must have achieved at least a PR, was not removed due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib, and must have at least a 6 month carfilzomib treatment-free interval from their last dose of carfilzomib * ECOG PS of 0 to 2 Exclusion Criteria * Primary refractory multiple myeloma * Waldenström macroglobulinemia * Multiple myeloma of IgM subtype * POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) * Plasma cell leukemia ( greater than 2…